Aromatase inhibitors for breast cancer prevention

Saranya Chumsri; Stephen Yu; Amanda Schech; Gauri Sabnis; Angela Brodie

doi:10.1007/978-3-319-27135-4_5

Aromatase inhibitors for breast cancer prevention

Saranya Chumsri, Stephen Yu, Amanda Schech, Gauri Sabnis, Angela Brodie

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

Original language	English (US)
Title of host publication	Trends in Breast Cancer Prevention
Publisher	Springer International Publishing
Pages	103-111
Number of pages	9
ISBN (Electronic)	9783319271354
ISBN (Print)	9783319271330
DOIs	https://doi.org/10.1007/978-3-319-27135-4_5
State	Published - Jan 1 2016

Keywords

Aromatase inhibitors
Breast cancer
Chemoprevention

ASJC Scopus subject areas

General Medicine
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1007/978-3-319-27135-4_5

Cite this

@inbook{b40905efb7524d3dabc7d35b3b78b3e5,

title = "Aromatase inhibitors for breast cancer prevention",

abstract = "Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.",

keywords = "Aromatase inhibitors, Breast cancer, Chemoprevention",

author = "Saranya Chumsri and Stephen Yu and Amanda Schech and Gauri Sabnis and Angela Brodie",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-27135-4_5",

language = "English (US)",

isbn = "9783319271330",

pages = "103--111",

booktitle = "Trends in Breast Cancer Prevention",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Aromatase inhibitors for breast cancer prevention

AU - Chumsri, Saranya

AU - Yu, Stephen

AU - Schech, Amanda

AU - Sabnis, Gauri

AU - Brodie, Angela

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2016.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

AB - Aromatase inhibitors (AIs) offer a new treatment option for breast cancer prevention without increased risks of venous thromboembolism and endometrial cancer. Compared to placebo, both exemestane and anastrozole signifi cantly reduced the risk of not only invasive breast cancer but also non-invasive lesions. AIs are associated with unique side effects, particularly musculoskeletal symptoms, vasomotor symptoms, and bone loss. However, these side effects are manageable. There appeared to be no difference in the incidence of cardiovascular disease and the difference in quality of life is numerically small.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Chemoprevention

UR - http://www.scopus.com/inward/record.url?scp=85008957439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008957439&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27135-4_5

DO - 10.1007/978-3-319-27135-4_5

M3 - Chapter

AN - SCOPUS:85008957439

SN - 9783319271330

SP - 103

EP - 111

BT - Trends in Breast Cancer Prevention

PB - Springer International Publishing

ER -

Aromatase inhibitors for breast cancer prevention

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this